Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The available research on L-carnitine includes several recent preclinical studies and completed clinical trials, though the evidence base shows some limitations.
Preclinical Research
Recent studies from 2026 have explored L-carnitine's role in various metabolic pathways. One study published in the Journal of Ethnopharmacology investigated a traditional Chinese medicine combination (Danshen-Chuanxiong) and found it may help with cerebral ischemia by regulating carnitine metabolism through CPT1/HIF-1α signaling pathways. Another study in Molecular Biology Reports examined how nicotinamide mononucleotide affects heart cell metabolism, with carnitine-related pathways (specifically CPT1A) playing a role in the mechanism.
Additional research has looked at metabolic factors in cardiovascular disease and different types of brain inflammation, with some studies identifying carnitine-related metabolites as potentially relevant biomarkers. However, these studies primarily focus on broader metabolic profiles rather than L-carnitine supplementation specifically.
Clinical Trials
Five completed Phase 2 clinical trials have tested L-carnitine in different conditions:
Alzheimer's Disease (NCT01320527): A completed Phase 2 trial tested a vitamin/nutraceutical formulation containing L-carnitine for Alzheimer's disease, though specific results are not detailed in the available information.
Dry Eye in Sjögren's Syndrome (NCT03953703): A completed Phase 2 trial investigated levocarnitine (the active form of L-carnitine) for treating dry eye symptoms in patients with Sjögren's syndrome.
Peritoneal Dialysis (NCT00755456): This completed Phase 2 trial examined whether an L-carnitine-containing dialysis solution could improve insulin sensitivity in patients on continuous peritoneal dialysis.
Spinal Muscular Atrophy (NCT00227266): A completed Phase 2 trial tested the combination of valproic acid and carnitine in patients with spinal muscular atrophy.
Myelodysplastic Syndrome (NCT02042482): A Phase 2/3 trial studied the combination of CoQ10 and L-carnitine for myelodysplastic syndrome, though the status is listed as unknown.
Limitations
The current evidence base has notable gaps. While several clinical trials have been completed, detailed results and sample sizes are not available in the provided information. The preclinical studies mainly examine L-carnitine as part of broader metabolic pathways rather than direct supplementation effects. More comprehensive trial data would be needed to draw definitive conclusions about L-carnitine's therapeutic potential across these various conditions.
This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering L-carnitine supplementation.